Marina Biotech elects Karis and Fletcher to board
This article was originally published in Scrip
Executive Summary
Marina Biotech, a nucleic acid-based drug discovery and development company, has elected James Karis, who has been a board member since 2009, chairman, succeeding co-chairmen Gregory Sessler and Peter Parker, who will both continue as board members. The company has also appointed R. John Fletcher to its board, replacing Dr Chiang Li who is retiring. Mr Fletcher is the founder and CEO of Fletcher Spaght.